Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session

36MO - Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer


02 Mar 2021


Mini Oral session


Adrian Sacher


Annals of Oncology (2021) 32 (suppl_1): S14-S19. 10.1016/annonc/annonc459


A. Sacher1, X. Le2, R. Cornelissen3, E. Shum4, M. Socinski5, J.R. Molina6, E. Haura7, J. Clarke8, G. Bhat9, F. Lebel10, M.C. Garassino11

Author affiliations

  • 1 Medical Oncology And Hematology Department, Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA
  • 2 Thoracic Head And Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US
  • 3 Pulmonary Medicine, Erasmus MC - University Medical Center, 3015 CE - Rotterdam/NL
  • 4 Medical Oncology, New York University Longone Health, 10016 - New York/US
  • 5 Medical Oncology, AdventHealth Cancer Institute, 32804 - Orlando/US
  • 6 Medical Oncology, Mayo Clinic, 55905 - Rochester/US
  • 7 Medical Oncology, Moffit Cancer Center, 33612 - Tampa/US
  • 8 Medical Oncology, Duke University, 27710 - Durham/US
  • 9 Clinical Science, Spectrum Pharmaceuticals, 92618 - Irvine/US
  • 10 Research & Development, Spectrum Pharmaceuticals, 92618 - Irvine/US
  • 11 Thoracic Unit, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, 20133 - Milan/IT


Login to access the resources on OncologyPRO.

Abstract 36MO


Effective treatment of patients with metastatic non-small cell lung cancer (mNSCLC) harboring EGFR or HER2 exon 20 insertion mutations represents a critical unmet need. Poziotinib is a potent, irreversible, tyrosine kinase inhibitor (TKI) being studied in a multi-cohort phase II study (ZENITH20). Poziotinib half-life of 7.2 hours and pharmacokinetic modeling suggests an opportunity to improve tolerability with a twice daily (BID) dosing schedule. Here we present efficacy data from once daily (QD) in treatment naïve patients as well as an exploratory study of BID dosing.


ZENITH20-3 enrolled treatment-naïve mNSCLC patients with EGFR exon 20 mutations at 16mg QD. Patients were treated until death, progression or significant toxicity. ZENITH20-5 treated patients with EGFR or HER2 exon 20 mutations in randomized arms of 10, 12, 16 mg QD or 6 and 8 mg BID. The endpoints were objective response rate (ORR per RECIST 1.1), duration of response (DOR), progression-free-survival (PFS) and safety.


In ZENITH20-3 (N=79), the median time of follow up was 9.2 months with 12 patients still receiving treatment. The intent-to-treat analysis showed an ORR of 27.8% (22/79; 95% CI: 18.4 – 39.1%) and disease control rate of 86.1%. 91% of all study patients had tumor reduction. The median DOR was 6.5 months and the median PFS was 7.2 months. Adverse event profile was similar to 2nd generation EGFR TKIs with ≥ grade 3 rash of 33% and diarrhea of 23%. Preliminary data from ZENITH20-5 (N=40) randomized cohorts of QD vs BID dosing (16mg QD vs 8mg BID; 12mg QD vs and 6mg BID) indicate that the expected AE rate was lower with BID dosing (31% vs. 21% and 27% vs. 16% respectively) in cycle 1. BID dosing schedules resulted in the relative reduction in dose interruptions by 38% and 52% respectively. Updated safety, tolerability and preliminary efficacy data will be presented.


Poziotinib demonstrated clinically meaningful activity in treatment-naïve mNSCLC patients with EGFR exon 20 mutations at 16 mg QD dosing. Preliminary data demonstrates improved tolerability and safety with BID dosing strategy and warrants further evaluation.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Spectrum Pharmaceuticals, Inc.


Spectrum Pharmaceuticals, Inc.


A. Sacher: Honoraria (institution), Advisory/Consultancy: AstraZeneca; Honoraria (institution), Advisory/Consultancy: Amgen; Honoraria (institution), Advisory/Consultancy: Merck; Honoraria (institution): Pfizer; Honoraria (institution), Advisory/Consultancy: Bayer; Honoraria (institution), Advisory/Consultancy: Genentech-Roche; Honoraria (institution), Advisory/Consultancy: Kisoji; Honoraria (institution), Advisory/Consultancy: BMS; Honoraria (institution): Tesaro. X. Le, M. Socinski, M.C. Garassino: Research grant/Funding (institution): Spectrum Pharmaceuticals. J. Clarke: Advisory/Consultancy: Spectrum Pharmaceuticals. G. Bhat, F. Lebel: Full/Part-time employment: Spectrum Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.